Update on the Opioid Epidemic: Perspective from a Women’s Addiction Treatment Facility

Tracy Frame, PharmD, BCACP
Belmont University College of Pharmacy
The Next Door Addiction Treatment Facility
Disclosures

• There are no relevant financial interests to disclose for myself or my spouse from within the last 12 months.
Objectives

- Review opioid properties
- Compare and contrast medication-assisted treatment (MAT) options available for opioid-use disorder (OUD)
- Discuss myths and truths of MAT
- Identify ethical issues in OUD
The Next Door

WE EXIST TO EMPOWER WOMEN FOR LIFETIME RECOVERY.
THE OPIOID EPIDEMIC BY THE NUMBERS

130+
People died every day from opioid-related drug overdoses\(^3\) (estimated)

10.3 m
People misused prescription opioids in 2018\(^1\)

47,600
People died from overdosing on opioids\(^2\)

2.0 million
People had an opioid use disorder in 2018\(^1\)

81,000
People used heroin for the first time\(^1\)

808,000
People used heroin in 2018\(^1\)

2 million
People misused prescription opioids for the first time\(^1\)

15,349
Deaths attributed to overdosing on heroin (in 12-month period ending February 2019)\(^2\)

32,656
Deaths attributed to overdosing on synthetic opioids other than methadone (in 12-month period ending February 2019)\(^2\)

SOURCES
1. 2019 National Survey on Drug Use and Health. Mortality in the United States, 2018
2. NCHS Data Brief No. 329, November 2018
Substance Use Disorder

• Addiction is a Disease
  – Preventable
  – Treatable

• Factors Increasing Risk
  – Biological,
    Environmental, Others

• Brain changes

Review of Opioids
Review of Opioids: Receptors

- 4 types of opioid receptors:
  - Delta (OP1), kappa (OP2), mu (OP3) and opioid-receptor-like-1 (ORL-1) which work in:
    - Brain, Brainstem, Spinal cord, Peripheral neurons, Intestine, Skin, Pituitary, Immune cells

![Table showing clinical effects of opioid receptors](https://www.pharmacytimes.com/contributor/jeffrey-fudin/2018/01/opioid-agonists-partial-agonists-antagonists-oh-my)
Review of Opioids: Opioid Affinity

- Affinity- how tightly it binds to the receptor
  - Dependent on opioid

Table 5. Mu Receptor Affinities of Various Opioids

<table>
<thead>
<tr>
<th>Opioids</th>
<th>Range of Ki Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levorphanol</td>
<td>0.19 to .23</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>0.21 to 1.5</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>0.4 to 0.6 (antagonist effects)</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.7 to 1.9</td>
</tr>
<tr>
<td>Methadone</td>
<td>0.72 to 5.6</td>
</tr>
<tr>
<td>Naloxone</td>
<td>1 to 3 (antagonist effects)</td>
</tr>
<tr>
<td>Morphine</td>
<td>1.02 to 4</td>
</tr>
<tr>
<td>Pentazocine</td>
<td>3.9 to 6.9</td>
</tr>
<tr>
<td>Codeine</td>
<td>65 to 135</td>
</tr>
</tbody>
</table>

Review of Opioids: Opioid Binding

- Agonist
  - Most opioids
  - Activate opioid receptors and cause the physiological and psychological effects we see with opioids
  - Effects increase until the receptor is fully activated and a maximum effect is reached, providing:
    - Pain relief
    - Euphoria, pinpoint pupils, constipation, nausea, sedation, mental clouding, impaired judgement, slurred speech, decreased anxiety, drop in blood pressure, respiratory depression
Review of Opioids: Opioid Binding

- **Partial Agonist**
  - Also activate opioid receptors
    - At low doses, partial and full agonists have similar effects
    - At high doses, partial agonists do not produce as great an effect as full (“ceiling effect”)

- **Antagonist**
  - Opioid antagonists bind to opioid receptors, but do not activate them
  - Do not cause any psychoactive effects, such as euphoria, but block the effects of competing agonists

- **Mixed agonist/antagonists**
  - Based on receptor and dose

### Table 3. Examples of Opioid by Receptor Binding

<table>
<thead>
<tr>
<th>Full Agonist</th>
<th>Partial Agonist</th>
<th>Mixed Agonist</th>
<th>Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heroin</td>
<td></td>
<td>Buprenorphine</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td></td>
<td>Butorphanol</td>
<td>Naltrexone</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td></td>
<td>Phenazocine</td>
<td></td>
</tr>
<tr>
<td>Levorphanol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meperidine</td>
<td>Buprenorphine</td>
<td>Butorphanol</td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>Butorphanol</td>
<td>Phenazocine</td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td></td>
<td>Nalbuphine</td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td></td>
<td>Morphine</td>
<td></td>
</tr>
<tr>
<td>Oxymorphone</td>
<td></td>
<td>Oxymorphone</td>
<td></td>
</tr>
</tbody>
</table>
Opioid Review Question

Which of the following would be considered to have a “ceiling effect”?

A. Methadone
B. Buprenorphine
C. Naloxone
D. Oxycodone
Medication-Assisted Treatment
Medication-Assisted Treatment

• What is Medication-Assisted Treatment (MAT)?
  – Use of medications along with counseling and behavioral therapies to treat substance use disorders and prevent overdose
  – TIP 63

SAMHSA 2020, https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat
MAT Medications

- Mechanism of action at mu-opioid receptor:
  - Agonist-
    - Methadone
  - Partial Agonist
    - Buprenorphine
  - Antagonist
    - Naltrexone

Image Credit: https://www.ablerecovery.net/medication-assisted-treatment-drug-abuse/
Methadone

- Schedule II controlled substance
- Long-acting, full mu-opioid agonist
- Oral dosage form
- Medically supervised withdrawal and maintenance (OTP)
  - Controls cravings
  - Blunts or block euphoria from illicit opioids
- Can be addictive and cause overdose

- Wide individual variability in half-life (8 to 59 hours)
- No ceiling effect, reaches steady state in about 5 days
- Individualized dosing → begin low dose and gradually increase with daily monitoring over days to weeks

Medications for Opioid Use Disorder. TIP 63. Available at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006
Methadone

- Drug-drug interactions
  - CYP450 3A4 primarily metabolizes methadone
  - Monitor for interactions

- Adverse effects and Cautions:
  - Opioid side effects
  - QTc prolongation
  - Respiratory depression

- Overdose - taking more than prescribed, as tolerance builds
Buprenorphine

- **Subutex®**
  - Buprenorphine sublingual
- **Bunavail®**
  - Buprenorphine *with* naloxone buccal film
- **Suboxone®**
  - Buprenorphine *with* naloxone sublingual film
- **Zubsolv®**
  - Buprenorphine *with* naloxone sublingual tablets

- **Probuphine®**
  - 6 month implant
- **Sublocade®**
  - Monthly injection
Buprenorphine

- Schedule III controlled substance
- High affinity, partial agonist at mu-opioid receptor, antagonist at kappa receptor
- Medically supervised withdrawal and maintenance
- Given with naloxone in maintenance
- Effective/maintenance dose is the dose that prevents withdrawal symptoms and cravings
- Physical dependence

Medications for Opioid Use Disorder. TIP 63. Available at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006
Buprenorphine

- Safer than methadone- less sedation and risk for respiratory depression
- Can also help with pain
- Initiate around 12-24 hours after last opioid or can precipitate withdrawal
- Long elimination half-life (24 to 69 hours)
- Drug-drug interactions due to CYP450 3A4 enzymes

Adverse effects and Cautions:
- Euphoria
- Opioid-like effects
- Peripheral edema
- Sedative effects (confusion, vomiting, extreme sleepiness, breathing problems)
- Especially in combination with benzodiazepines or other CNS depressants

Medications for Opioid Use Disorder. TIP 63. Available at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006
Naltrexone

- ReVia® (50 mg oral tablets)
- Vivitrol® (380 mg extended-release injection)

- Opioid antagonist
  - Reduces opioid cravings
  - No euphoria or sedative effects of opioids if patient were to take some
- Prevention of relapse following medically supervised withdrawal
- Not a control substance and not addictive
Naltrexone

- Patients need to be opioid free for at least 3-14 days before starting (depending on opioid used) or precipitate withdrawal

- Minimal drug-drug interactions

- Adverse Effects and Cautions:
  - Nausea, anxiety, insomnia, suicidiality, anorexia, dizziness, fatigue
  - Intramuscular: pain, swelling, cellulitis, abscess, necrosis (surgical intervention)
  - Risk of overdose, injection site reactions, hepatotoxicity
MAT Review Question

• Which of the following MAT options would be easiest to transition a patient onto following opioid use?
  A. Methadone
  B. Buprenorphine
  C. Naltrexone
Myths about MAT

• “They are just substituting one drug for another”
• “MAT is a moral failure or a matter of not having enough willpower—the person should pray more”
• “MAT is only for the weak who can’t do it without medications”
• “MAT is only for the short term”
• “MAT increases the risk for overdose”
• “My patient’s condition is not severe enough for MAT”
• “MAT is a crutch on their road to recovery, abstinence is the only way that works”

National Council for Behavioral Health. MAT Myths vs Facts. Available at: https://www.thenationalcouncil.org/mat/mf_1_30/
Truths about MAT

- Reduces or blocks cravings
- Reduces the chance of relapse
- Decreases or stops illicit opiate use
- Increases retention in treatment
- Improves quality of life
- Improves health and functioning

- In many cases, without MAT, abstinence-based treatment alone for opioid use disorder can have fatal consequences

SAMHSA 2020, https://www.samhsa.gov/medication-assisted-treatment/treatment#medications-used-in-mat
Ethical Issues

- Dispensing opioids vs dispensing MAT
- Dispensing clean needles
- Dispensing naloxone
- So many more...
As a Christ-Following Pharmacist, Addiction Treatment Is...
Addiction Treatment is Loving like Jesus

• Requires person-centered care...a relationship with the patient!

• Meet the patient where they are—just as Jesus did!

  – Mark 2:17- On hearing this, Jesus said to them, "It is not the healthy who need a doctor, but the sick. I have not come to call the righteous, but sinners.”

https://biblehub.com/mark/2-17.htm
Addiction Treatment is a Whole Person Approach

• Whole person approach:
  • Medical
  • Spiritual
  • Psychological
  • Social
  • Vocational
  • Legal
Addiction Treatment is Not One Size Fits All

• It’s not just about giving or refusing medications as a pharmacist

• MAT= a tool on the road to recovery
  • Some may need medications, some may not
  • If they do, it is not a failure or “lack of faith” on their part
Addiction Treatment is Realizing it is a Chronic Disease

- Risk of Relapse!
- Recognize the warning signs
- Identify signs of opioid use and withdraw
- Say something
- Be an accountability partner
Addiction Treatment is Getting Involved

• Be aware and willing to help a patient—empathy and action!
• Get involved with patients who are struggling with addiction
• Get involved with patients who are in recovery
• Get involved in organizations
Addiction Treatment is Praying

• Praying for:
  – Our patients
  – Our minds to fully self-reflect in identifying our own biases and stereotypes
  – Our ability to recognize when a patient needs help
  – Our heart to serve each patient as we would if it were Jesus
• Think of a patient who has come to your pharmacy. Looking back at your interactions with him or her, is there something you would have changed or done better when helping them in their recovery?

• Develop a list for yourself of what else helping patients with addiction treatment might look like for you.
Final Thoughts

• People are dying every single day.

• Gave a commitment to our profession, but most importantly to Jesus. To serve both our patients and Him well.
Questions?